AZN vs LBRX
AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline. LBRX: LB Pharmaceuticals is a late-stage biopharmaceutical firm developing LB-102, a novel benzamide candidate aimed at becoming a first-in-class treatment for schizophrenia and mood disorders in the U.S. market.
Side-by-side fundamentals
| Metric | AZN | LBRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $169.73 | $35.84 | |
| Market cap as of 2026-07-23 | $193.7B | $921M | |
| P/E as of 2026-07-23 | 24.93 | n/a | |
| PEG as of 2026-07-23 | 2.64 | n/a | |
| Net margin as of 2026-07-23 | +17.2% | n/a | |
| Gross margin as of 2026-07-23 | +81.4% | n/a | |
| Operating margin as of 2026-07-23 | +23.7% | n/a | |
| ROE as of 2026-07-23 | +22.3% | -17.7% | AZN higher |
| ROA as of 2026-07-23 | +9.1% | -16.9% | AZN higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | LBRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | n/a | |
| Dividend yield as of 2026-07-23 | +1.9% | n/a | |
| Beta as of 2026-07-23 | 1.38 | 1.30 | |
| 1-year return as of 2026-07-22 close | +17.0% | +45.1% | LBRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.